Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Assets Average (2016 - 2025)

Historic Assets Average for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $4.2 million.

  • Alaunos Therapeutics' Assets Average rose 280.75% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 280.75%. This contributed to the annual value of $5.5 million for FY2024, which is 8494.81% down from last year.
  • As of Q3 2025, Alaunos Therapeutics' Assets Average stood at $4.2 million, which was up 280.75% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Alaunos Therapeutics' Assets Average peaked at $137.4 million during Q1 2021, and registered a low of $2.4 million during Q1 2025.
  • For the 5-year period, Alaunos Therapeutics' Assets Average averaged around $49.4 million, with its median value being $38.3 million (2023).
  • Per our database at Business Quant, Alaunos Therapeutics' Assets Average crashed by 8740.92% in 2024 and then surged by 280.75% in 2025.
  • Over the past 5 years, Alaunos Therapeutics' Assets Average (Quarter) stood at $104.3 million in 2021, then crashed by 36.59% to $66.1 million in 2022, then crashed by 79.06% to $13.9 million in 2023, then plummeted by 77.24% to $3.2 million in 2024, then skyrocketed by 34.16% to $4.2 million in 2025.
  • Its Assets Average was $4.2 million in Q3 2025, compared to $3.4 million in Q2 2025 and $2.4 million in Q1 2025.